NCT02495129View on ClinicalTrials.gov

Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Primary Sjögren's Syndrome
Interventions
DRUG

VAY736 lower dose

Patients will receive a total number of 3 monthly subcutaneous injections with the lower dose of VAY736

DRUG

VAY736 higher dose

Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY